Addex Therapeutics (SIX: ADXN.SW) is a clinical-stage biotechnology company focused on the development of allosteric modulators to treat a wide range of central nervous system (CNS) disorders. The Company’s lead program is dipraglurant for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease (PD). PD affects approximately 1.5% of people over the age of 65. As the disease progresses, the majority of patients will progress to having some degree of dyskinesia during peak levodopa exposure. Addex has successfully completed a Phase II study of dipraglurant with support from the Michael J. Fox Foundation and expects to launch a pivotal Phase III study in the second half of 2017.